Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImugeneASX:IMU Debt-to-Equity is 0.12 as of Dec. 2025, which is 1100% above its 10-year median of 0.01. The stock has 4 warning signs investors should review. Among 965 Biotechnology companies, Imugene ranks better than 57.2% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Imugene's Debt-to-Equity or its related term are showing as below:
ASX:IMU'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.24
Current: 0.12
During the past 13 years, the highest Debt-to-Equity Ratio of Imugene was 0.24. The lowest was 0.00. And the median was 0.01.
ASX:IMU's Debt-to-Equity is ranked better than 57.2% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs ASX:IMU: 0.12
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Imugene Debt-to-Equity Related Terms
Imugene Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Imugene's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IMU vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Imugene's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imugene Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Imugene's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Imugene's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imugene (ASX:IMU) has a Debt-to-Equity of 0.12 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Imugene and its competitors. This is 1100% above median its historical median of 0.01. According to the industry distribution chart, Imugene ranks #413 out of 965 companies in the Biotechnology industry, placing it in the top 42.8%.
Is Imugene's Debt-to-Equity too high?
Imugene's current Debt-to-Equity of 0.12 is 1100% above median its 10-year median of 0.01. The Biotechnology industry median Debt-to-Equity is 0.16. Imugene's value of 0.12 is 25% below this industry median. Based on the distribution chart, Imugene ranks #413 out of 965 companies in the Biotechnology industry, which is above the industry midpoint.
How does Imugene's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Imugene ranks #413 out of 965 companies for Debt-to-Equity. This puts Imugene in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Imugene's value of 0.12 is 25% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.16, Imugene has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imugene's current Debt-to-Equity of 0.12 is 25% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Imugene and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imugene's current Debt-to-Equity is 0.12, which is 1100% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imugene stock overvalued right now?
Imugene (ASX:IMU) has a current Debt-to-Equity of 0.12. The current Debt-to-Equity is 0.12, which is 1100% above median its 10-year median of 0.01 and 25% below the Biotechnology industry median of 0.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Imugene (ASX:IMU), the current Debt-to-Equity is 0.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMU has been successfully added to your 
